Search Results

By Caroline Helwick  / Friday, December 13, 2013 3:29 PM

CALGB 40603 Trial Supports Adding Carboplatin to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer

The addition of carboplatin to a neoadjuvant regimen significantly increased the rate of pathologic complete response in patients with triple-negative breast cancer. The results from the CALGB/Alliance 40603 study were reported at the 2013 San Antonio Breast Cancer Symposium (Abstract S5-01)....